Supplemental Table 4 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy

Leanne G. Ahronian; Soumyadip Sahu; Minjie Zhang; Ayushi Patel; Ke Geng; Reshmee Bhattacharya; Gerald S. Falchook; Jonathan W. Goldman; Alexander I. Spira; Salman R. Punekar; David R. Spigel; Judy S. Wang; Ferdinandos Skoulidis; Janaye Stephens; Mary Meynardie; Jaylen M. Powell; Alfonso Lopez; Michela Ranieri; Magdalena Ploszaj; Yi Jer Tan; Yeuan Ting Lee; Yi Yu; Jiehui Deng; Ting Chen; Patrick McCarren; Alice Tsai; Suleman S. Hussain; Brian Doyon; Kenjie Amemiya; Jacques Ermolieff; Preksha Shahagadkar; Nikitha M. Das; Lauren R. Flynn; Julie A. Shields; Laney Danielczyk; Brian J. McMillan; Andre Mignault; Samuel R. Meier; Hsin‐Jung Wu; David J. Guerin; Douglas A. Whittington; Chengyin Min; Iga Sienczylo; John P. Maxwell; Heather DiBenedetto; Hideo Watanabe; Brian B. Haines; Alan Huang; Adam S. Crystal; Jannik N. Andersen; Xinyuan Wu; Kwok‐Kin Wong

doi:10.1158/0008-5472.30363268

October 15, 2025Open Access

Supplemental Table 4 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy

View Full Paper

Ask AI

Bookmark

Share

Key Points

The CoREST inhibitor significantly sensitized STK11-mutant tumors to anti–PD-1 immunotherapy, improving treatment efficacy.
CRISPR score results indicated a notable comparison of MC38_sgSTK11 tumors against control tumors (MC38_sgNTC) in C57BL/6 mice.
The approach utilized CRISPR technology in a mouse model to critically assess the resistance mechanisms to anti–PD-1 therapy.
This research highlights the potential for combining small-molecule inhibitors with immunotherapy in targeting specific tumor mutations.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Observational analysis shows that a small-molecule CoREST inhibitor enhances response to anti–PD-1 in STK11-mutant tumors, suggesting potential therapeutic benefits.

Abstract

CRISPR score results for the comparison of MC38_sgSTK11 tumors to MC38_sgNTC tumors in C57BL/6 mice treated with anti-PD1

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ahronian et al. (2025) studied this question.

synapsesocial.com/papers/68f199c5de32064e504dce05 https://doi.org/10.1158/0008-5472.30363268

View Full Paper

Ask AI

Bookmark

Share

Supplemental Table 4 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Supplemental Table 4 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading